News

The new plant, supported by NETDA, a Chinese development organization, will include production of active pharmaceutical ingredients and intermediates in its initial phase. The company is expecting to

The acquisition will enable Brenntag to expand its existing specialty product portfolio in the region for industries like pharmaceuticals, personal care, food & beverage as well as coatings.

The CTx-0294886, a potent small molecule inhibitor of Focal Adhesion Kinase (FAK) and Vascular Endothelial Growth Factor Receptor 3 (VEGFR3), was compared with that of CTx-0294945, a potent

The company has randomised 75 patients with Hereditary Angioedema (HAE) in its ongoing US pivotal Study 1310, out of which 53 experienced a repeat attack or achieved a

The open-label, multicenter studies will evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc and rFIXFc in previously-treated children with severe hemophilia A or B under the age of

The company also revealed aldoxorubucin as the new generic name for INNO-206, the conjugate which comprises the protein-binding linker technology, a chemotherapeutic drug doxorubicin. CytRx president and CEO

The letter was issued in late May based on inspections conducted in December and January, according to the Associated Press. The US Food and Drug Administration has issued

According to the revised agreement, NPS will earn a one-time $25m payment in July 2012 in exchange for its rights to receive royalties under the license agreement that

ERT is a technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives. ERT CEO Jeffrey Litwin